CpG 1018 | DVAX Message Board Posts

Dynavax Technologies Corporation

  DVAX website
  • Membership Drive Update: In the first 48 hours we've hit almost 20% of our goal. An encouraging start to be sure, but we can't stop now. We need to pull enough subscription revenue forward to counter severe cash flow deficits resulting from a dramatic slow-down in ad spend thanks to the global pandemic which shows no signs of letting up in the near-term. We're doing everything in our power to keep our heads above some very choppy water, but we can't do it alone. We need your help. So if you've ever thought about giving our premium service a try, there's no better time to do it than right now by taking advantage of one of our discounted multi-year plans. Thanks in advance for your continued loyalty & support! 

  • Limited Premium Membership Offer
    Choose a Plan, Save Money & Help Us Survive the Pandemic

    Lifetime @ $399 (only 24 left) 5-yrs @ $199 (only 30 left) 2-yrs @ $99 (only 27 left)

DVAX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1758 of 1779  at  8/7/2020 6:18:25 PM  by

fairvalueforyou

The following message was updated on 8/7/2020 6:37:08 PM.

 In response to msg 1757 by  newtron
view thread

Re: CpG 1018

  
GSK AS-01 and AS-03 are all used in their approved vaccines, Matrix-M used in NAVX nanoFlu vaccine just passed phase III trial earlier this year in March, and exactly same platform/technology has been used to develop SARS, MERS, and Ebola vaccines with very excellent NHP and phase I immunological data. No wonder, NVAX platform/technology with Matrix-M is working well for its covid19 vaccine, its NHP data and nanoFlu phase III success finally convinced CEPI to give NVAX the largest fund ever - $388 million in total, then excellent NHP data including challenge data forced OWS to give NAVX $1.6B fund. Most people don't know, Trump administration/OWS forced NVAX to find BP partner to gain BARDA fund earlier in this year, NVAX did not give in, eventually with CEPI's help, won OWS fund as well as leveled ground to compete with big boys in OWS covid19 phase III trials - head to head comparing the data by OWS lab with exactly same trial protocols. So far, by NHP data and phase I immunological data, NVAX covid19 vaccine data is far superior, and data does not lie, and the NVAX covid19 vaccine superiority will be see in OWS phase III trial results. The world knows which front runner vaccine is best one, and Japan just licensed NVAX covid19 vaccine manufacturing to supply 250 million doses annually for Japanese people, the world largest vaccine producer Serum Institution of India also signed agreement to fill/finish NVAX vaccine to supply India, and other low to middle class counties. It is just matter of time, US, EU, UK, Australia, New Zealand, Singapore, Taiwan, rich middle east oil producer countries, and many middle-upper class countries will demand the best covid19 vaccine - NVAX covid19 vaccine.
Which government would want to take inferior covid19 vaccine when a superior one is available?
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 59
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.


Loading...